PDE5 inhibitors have been shown to have various macrovascular, microvascular and metabolic benefits in diabetes mellitus, and in a large study of men with type 2 diabetes mellitus the agents were found to significantly reduce patients' risk of death from any cause. It is unclear to what extent this observation reflects the protective effects of PDE5 inhibitors against cardiovascular and renal disease.